Table 3 Key events surrounding voluntary recalls of MoM
From: Halo and spillover effect illustrations for selected beneficial medical devices and drugs
Product | Year | Event |
|---|---|---|
MoM Hip Implants | 1930s | MoM hip implants first used for resurfacing and total replacement |
1950s | MoP implant replaces early gen MoMs, lower early revision rates | |
1950s-1970s | MoP revision rates favorable at 5 and 10Â yrs. post-implantation | |
1970s-1980s | Post ~ 15 years, MoP disintegrates, causes local inflammation, failure | |
1990s | New gen MoMs in Europe; early revision rates comparable to MoP | |
2003 | New MoMs sold in the US | |
2003 | DePuy ASR XL Acetabular Hip System introduced to Europe | |
2005 | DePuy ASR XL Acetabular Hip System introduced to US | |
2004- 2012 | MoM Case reports: inflammation, nervous system and heart effects | |
2008 | Zimmer Durom AS MoM withdrawn (US) | |
2008-2011 | Australia and UK hip implant registries: increased rates of early revision for ASR XL Acetabular Hip System | |
2008-2011 | Reported increased early revision rates (certain MoMs): 3 manufacturers remove devices from markets | |
2009 | DePuy conducts a voluntary recall in Australia | |
2010 | Worldwide recall of the DePuy ASR product | |
2012 | Smith and Nephew withdraw R3 Acetabular System with R3 metal liners (US): reported elevated early revision rates in conjunction with the Birmingham Hip Resurfacing System | |
Post-recall | Negative press articles and personal injury litigation ensue in the US |